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Minichromosome maintenance protein 6 (MCM6) is one of six proteins of the MCM family which are involved in the initiation of
DNA replication and thus represent a marker of proliferating cells. Since the level of cell proliferation is the most valuable predictor of
survival in mantle cell lymphoma (MCL), we investigated lymph node biopsy specimens from 70 patients immunohistochemically with
a monoclonal antibody against MCM6. The percentage of MCM6 expressing lymphoma cells ranged from 12.0 to 95.6%, with a mean
of 61.0%, and was significantly higher than the percentage of Ki-67-positive cells (Po0.0001). Surprisingly, the ratio of MCM6-positive
cells to Ki-67-positive cells was higher than in normal stimulated peripheral blood mononuclear cells, indicating a cell early G1-phase
arrest in MCL. A high MCM6 expression level of more than 75% positive cells was associated with a significantly shorter overall
survival time (16 months) compared to MCL with a low MCM6 expression level of less than 25% (no median reached, Po0.0001).
Multivariate analysis revealed MCM6 to be an independent predictor of survival that is superior to the international prognostic factor
and the Ki-67 index. Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the
most promising marker for predicting the outcome in MCL.
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Mantle cell lymphoma (MCL) is a B-cell neoplasm characterised by
a typical immunophenotype and the chromosomal translocation
t(11;14) (Tsujimoto et al, 1984; Campo et al, 1999; Bertoni et al,
2004). The clinical course of MCL, although heterogeneous, is
usually poor, with a survival time of 3–4 years. For several years a
high proliferation rate, as measured by counting the number of
mitotic figures or of Ki-67-expressing cells, has been recognised as
a marker of poor prognosis (Lardelli et al, 1990; Velders et al, 1996;
Raty et al, 2002). However, due to the lack of data from prospective
trials and the limited predictive power of the markers available so
far, cell proliferation has rarely been used for clinical decision-
making in MCL. Studies of gene expression profiling demonstrated
that a set of genes, designated as the proliferation signature, can
predict the clinical outcome of patients with MCL with so far
unrivaled precision (Martinez et al, 2003; Rosenwald et al, 2003;
Ek et al, 2004). These studies have stimulated the search for
new immunohistochemical markers of proliferation that might
take the place of gene expression profiling as a predictor of
outcome in MCL.
Minichromosome maintenance (MCM) proteins play an impor-
tant role in the replication of eukaryotic DNA by binding to
chromatin before the initiation of DNA replication (Fujita et al,
1997; Ogawa et al, 1999). Minichromosome maintenance protein 6
(MCM6) is one of six members (MCM2–7) of the MCM family
(Lindner et al, 2002) and consists of 821 amino acids with a
molecular mass of 105kDa (Heidebrecht et al, 2001). We have
recently developed a specific monoclonal antibody against MCM6
(Ki-MCM6) (Heidebrecht et al, 2001) that enables the accurate
detection of MCM6 in paraffin-embedded tissue (Heidebrecht
et al, 2001; Helfenstein et al, 2004). Using Ki-MCM6, Heidebrecht
et al (2001) showed that MCM6 is detectable in nucleosols or
bound to nuclear chromatin during the entire cell cycle G1, S, G2
and M phases, but is absent in G0 phase (Labib et al, 2001). Despite
this similar expression pattern of MCM6 and Ki-67 during the cell
cycle phases (positive in G1, S, G2 and M phases), detailed cell
cycle analysis reveals differences between both markers. During
the early G1 phase Ki-67 is undetectable, whereas MCM6 is
expressed in the entire G1 phase. Therefore, a small subset of about
20% of proliferating cells in early G1 phase could be detected by
MCM6 and not by Ki-67 in stimulated peripheral blood mono-
nuclear cells (Heidebrecht et al, 2001).
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sThe clinical relevance of MCM proteins as proliferation markers
has been investigated immunohistochemically in several different
malignant tumours (Freeman et al, 1999), for example, non-small-
cell lung cancer (Ramnath et al, 2001), prostate cancer (Meng et al,
2001; Padmanabhan et al, 2004), oral squamous cell carcinoma
(Kodani et al, 2003), chondrosarcoma (Helfenstein et al, 2004),
oligodendroglial tumours (Wharton et al, 2001, 2004), oesophageal
neoplasm (Going et al, 2002), renal cell carcinoma (Dudderidge
et al, 2005), breast cancer (Gonzalez et al, 2004), endometrial
carcinoma (Li et al, 2005) and thyroid carcinoma (Guida et al,
2005). Most of these studies focused on the detection of MCM2
(Freeman et al, 1999; Chatrath et al, 2003; Davidson et al, 2003;
Kodani et al, 2003; Scott et al, 2004). So far only few investiga-
tions studied MCM6 expression (Labib et al, 2001; Helfenstein
et al, 2004).
The MCM2 expression was also analysed in 36 patients with
malignant B-cell lymphomas, including 11 cases with MCL
(Obermann et al, 2005). The authors included also Ki-67 and
geminin (Lygerou and Nurse, 2000; Wohlschlegel et al, 2000;
Madine and Laskey, 2001) in their study and could demonstrate
that low-grade lymphomas reside in an ‘in-cycle’ G1 state and
not in G0. In this very important study of Obermann et al (2005),
the authors did not analyse the MCM2 expression in relation to
clinical data.
The aim of this study was to investigate MCM as a new
proliferation marker in a large group of patients with MCL and to
correlate the results with established prognostic factors for this
disease. Since we have developed an antibody that accurately
identifies MCM6 in paraffin-embedded tissues, an expression
pattern that was tested in normal peripheral blood mononuclear
cells (Heidebrecht et al, 2001), we chose this antibody to determine
MCM protein expression in this lymphoma.
PATIENTS AND METHODS
Biopsy specimens (lymph nodes only) from 70 previously
untreated patients (Table 1) from two trials (1975 and 1985)
(Brittinger et al, 1984; Meusers et al, 1989) were recut and stained
with haematoxylin and eosin, Giemsa and Gomori silver impreg-
nation. The cytology was classified according to the WHO
classification of MCL into classical and blastoid subtypes (Jaffe
et al, 2001). The diagnosis of MCL was verified by two reference
pathologists from the European Mantle Cell Lymphoma Network
(MT and RP).
Antibodies and immunohistochemical staining
The immunohistochemical investigation was performed as des-
cribed previously (Schrader et al, 2004). All sections were stained
with antibodies against CD3 (dilution 1:20) (DAKO, Hamburg,
Germany), CD5 (dilution 1:25) (Novocastra, Newcastle, UK),
CD20 (dilution 1:5) (DAKO), CD23 (dilution 1:20) (Novocastra),
Table 1 Univariate analysis of prognostic factors in relation to MCM6 expression
Overall survival MCM6 expression (%)
N Median (months) P-value Mean7s.d. Median Range P-value
Age
o60 28 37 0.002 55.5723.5 55.0 14.8–90.6 0.098
460 42 23 64.6719.8 66.2 12.0–95.6
Sex
Male 57 29 0.688 61.0721.3 65.4 12.0–95.6 0.605
Female 13 28.8 58.1724.2 60.4 14.8–90.4
B-symptoms
Yes 25 17.0 0.002 67.8718.5 70.0 25.8–91.8 0.027
No 43 35.7 55.9722.3 57.0 12.0–95.6
BM infiltration
Yes 42 28.0 0.138 62.1719.7 65.6 12.0–90.6 0.488
No 27 33.0 58.2724.6 57.0 14.8–95.6
Stage
1+2 5 42.3 0.249 57.3719.6 56.3 33.6–87.9 0.638
3+4 59 28.0 62.1721.9 66.0 12.0–95.6
Status (WHO)
0–1 53 31.0 0.013 58.3721.7 60.4 12.0–95.6 0.014
X2 15 19.9 73.5716.6 74.0 35.6–90.6
Extranodal
Yes 58 29.0 0.157 60.6721.5 65.7 12.0–92.8 0.773
No 12 28.8 62.6723.7 62.3 14.8–95.6
LDH
o240 51 29.0 0.043 60.6721.5 63.2 12.0–95.6 0.055
4240 13 17.9 73.1715.4 73.2 37.2–91.8
IPI
0–1 17 40.0 0.007 53.0722.9 56.3 14.8–87.9 0.082
X2 53 25.4 63.5720.9 66.4 12.0–95.6
BM¼bone marrow; stage¼Ann Arbor stage; status¼performance status; extranodal¼extranodal involvement; LDH¼lactate dehydrogenase; IPI¼International Prognostic
Index; full data are not availble for all patients.
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scyclin-D1 (dilution 1:20) (Novocastra), MCM6 (dilution 1:1, cell
culture supernatant) (Ki-MCM6, Department of Hematopathology,
University of Kiel, Germany) and anti-Ki-67 (dilution 1:1, cell
culture supernatant) (Ki-S5, Department of Hematopathology,
University of Kiel, Germany). The stainings were evaluated by
investigators blinded to the clinical information. In each stained
section 500 neoplastic cells were counted. The MCM6 index was
calculated as the percentage of positive nuclei. Only nuclear
staining was counted as MCM6 positive.
Tonsil tissue was used as positive controls; negative control
samples were incubated with serum instead of the primary
antibody.
Statistical methods
For the statistical tests SPSS (SPSS Inc., version 11, Chicago, IL,
USA) was used. Various parameters were analysed statistically by
two-sided t-test and the correlation coefficient, as indicated.
Overall survival analysis (univariate) was analysed by the Kaplan–
Meier method. Differences in significance (Pp0.05) were assessed
by means of the log-rank test. All clinical parameters were also
compared by means of a multivariate Cox regression analysis
using a stepwise (forward and backward) conditional approach.
RESULTS
In 57 cases of MCL (81.4%) cytological analysis revealed a classical
cytology and in 13 cases (18.6%) a blastoid cytological subtype.
Immunophenotyping showed coexpression of CD20 and CD5 in all
cases and negativity of the tumour cells for CD23. Cyclin D1
staining was positive in 69 cases (98.6%). In one case (1.4%) cyclin
D1 staining could not be evaluated for technical reasons.
Minichromosome maintenance protein 6 staining was restricted
to the cell nucleus. The expression level ranged from 12.0 to 95.6%,
with a median of 64.6% and a mean of 61.0% (Figures 1A and B).
We retrieved data on Ki-67 expression from our previous
investigation on the same collection of samples (Schrader et al,
2004). As expected, the MCM6 index was significantly higher than
the Ki-67 index (Figure 2, Po0.0001), with a mean for Ki-67 of
19.8%, compared to 61.0% for MCM6. Also not unexpectedly, the
two markers showed a significant correlation (Figure 3,
Po0.0001). Surprisingly, cytological variants like the blastoid
variant did not differ in their MCM6 expression level (P¼0.2672).
In contrast, in our previous and other studies (Lardelli et al, 1990;
Ott et al, 1997; Campo et al, 1999), the Ki-67 index was
significantly higher in blastoid variants than in cases with classical
cytology. By calculating the ratio of MCM6 and Ki-67, the majority
of cases had high indices (mean: 4.774.6).
Univariate analysis of MCM6 expression in relation to clinical
characteristics revealed no significant differences concerning age,
sex, stage of the disease, bone marrow infiltration, extranodal
involvement, lactate dehydrogenase level and IPI score (Table 1).
The only significant differences concerned B-symptoms and WHO
status (Table 1). A multivariate analysis of 52 patients with
complete data for all variables showed that only MCM6 expression
(Po0.0001) and IPI (P¼0.0018) were prognostic factors for the
clinical outcome (Table 2) in our group of patients.
The patients were ranked according to their MCM6 expression
level and divided into four equal quartiles (Table 3). Figure 4
shows the Kaplan–Meier analysis of overall survival time for
patients in different quartiles. These data indicate that the MCM
expression can identify patients with a good and a poor prognosis.
The median survival times for the quartiles are listed in Table 3. In
accordance with Ramnath et al (2001), we analysed the MCM
expression in four categories. Patients with an MCM6 expression
level of lower than 25% had not yet reached a median survival, in
contrast to 38.2 months for the group with 25–50%, 30 months for
the group with 50–75% and 16.0 months for patients with more
than 75% (Figure 5 and Table 3, Po0.0001).
DISCUSSION
Minichromosome maintenance proteins are components of
the prereplicative complex and are essential for the initiation
of DNA replication (Labib et al, 2001). With the development of
Figure 1 (A) Mantle cell lymphoma with a low level of MCM6
expression (o25%). APAAP staining, magnification  1000. (B) Very high
MCM6 expression (475%). APAAP staining, magnification  1000.
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Figure 2 Minichromosome maintenance protein 6 and Ki-67 expression
as % positive cells in all cases.
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proliferation markers for the analysis of archived tissue has
become possible. To date, most studies have focused on MCM2
expression, for example, in oral squamous cell carcinomas (Kodani
et al, 2003), prostate cancer (Meng et al, 2001; Padmanabhan et al,
2004) and ovarian serous neoplasms (Scott et al, 2004) chondro-
sarcoma (Helfenstein et al, 2004), oligodendroglial tumours
(Wharton et al, 2001, 2004), oesophageal neoplasm (Going et al,
2002), renal cell carcinoma (Dudderidge et al, 2005), breast cancer
(Gonzalez et al, 2004), endometrial carcinoma (Li et al, 2005) and
thyroid carcinoma (Guida et al, 2005).
In a large study, Ramnath et al (2001) examined 221 patients
with lung cell cancer immunohistochemically for MCM2 expres-
sion and found MCM2 expression to be an independent prognostic
factor for survival. In this study, patients with MCM2 expression in
less than 25% of the tumour cells had a significantly better
prognosis than patients with tumours with a higher MCM2 index.
Additional to the study by Ramnath, only few studies have
investigated MCM proteins immunohistochemically. Brake et al
(2003) focused on MCM7 in cervical cancer and Helfenstein et al
(2004) on MCM6 in chondrosarcoma using the monoclonal
antibody Ki-MCM6, also employed in our study.
The MCM expression in peripheral B-cell lymphomas was
investigated for the first time by Obermann et al (2005), who could
demonstrate that also in MCLs the majority of lymphoma cells
reside in the cell cycle phases G1, but not in S/G2/M. These data
are in line with our results of repp86 in a large series of 94 patients
with MCL (Schrader et al, 2005). Repp86 is a spindle apparatus-
associated protein expressed only during S/G2/M, absent in G1 and
G0, and thus displaying the same cell cycle expression pattern like
geminin (Heidebrecht et al, 1997, 2003; Lygerou and Nurse, 2000;
Wohlschlegel et al, 2000; Madine and Laskey, 2001; Hodgson et al,
2002). We could demonstrate that the majority of the 94 cases have
lower repp86 expression than Ki-67, and this indicates a G1 arrest
in the subset of cases in our collective.
Mantle cell lymphomas are mature B-cell neoplasms with a poor
prognosis. Measures to predict the heterogeneous clinical outcome
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Figure 3 Correlation analysis of MCM6 and Ki-67 expression.
Table 2 Uni- and multivariate Cox regression analysis of all prognostic factors with respect to overall survival in 52 MCL patients with complete data
available (out of 70 patients)
P-value
Characteristics Reference level Univariate Multivariate
MCM6 expression 0–25% vs 425–50% vs 450–75% vs 475% o0.0001 o0.0001
Ki-67 expression p10% vs 410% 0.0045 0.2473
International prognostic index 0–1 vs X2 0.0011 0.0018
LDH Normal vs elevated 0.0841 0.7638
Age o60 vs 460 0.0083 0.5001
Sex Male vs female 0.6679 0.8449
B-symptoms Yes vs no 0.0241 0.4884
Bone marrow infiltration Yes vs no 0.0650 0.9970
Stage 1+2 vs 3+4 0.6677 0.7943
Performance status (WHO) 0+1 vs X2 0.0246 0.4430
Extranodal involvement Yes vs no 0.0749 0.3797
Table 3 Results of the analysis of MCM6 expression in relation to the
overall survival time in 70 patients with MCL
MCM6 expression n (%)
Median OS
(months)
5-year
survival (%) P-value
Quartile 1
12.0–44.7%
18 (25.7) 40.0 22.2 o0.0001
Quartile 2
49.0–65.4%
18 (25.7) 36.0 11.1
Quartile 3
65.8–77.8%
17 (24.3) 25.4 0
Quartile 4
79.2–95.6%
17 (24.3) 17.5 0
0–25% 5 (7.1) Not reached 60.0 o0.0001
425–50% 14 (20.0) 38.2 14.3
450–75% 32 (45.7) 30.0 6.3
475–100% 19 (27.1) 16.0 0
OS¼overall survival time.
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Figure 4 Kaplan–Meier analysis of the overall survival time of patients
with MCL. Patients were ranked according to their MCM6 expression level
and divided into four equal quartiles.
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sof the disease are needed to guide clinical decision-making. Studies
of gene expression profiling in MCL have stressed the importance
of cell proliferation for the clinical outcome. Rosenwald et al
(2003) summarised predictive genes for survival as the ‘prolifera-
tion signature’ since most of these genes are thought to be involved
in cell cycle progression, mitosis or DNA replication. Data from
gene expression profiling experiments are describing transcrip-
tional changes of mRNA and cannot be necessarily be translated
into protein expression. Furthermore, due to the high costs and
technical obstacles like the need for fresh material, gene expression
profiling is limited in its use for routine analysis of tumour
samples. For these reasons, it is useful to confirm results based on
gene expression profiling on the protein level with, for example, by
immunohistochemistry. In a previous study, we studied topoi-
somerase IIa expression by immunohistochemistry and were able
to confirm the results from Rosenwald et al (Schrader et al, 2004).
Since mRNA expression of MCM2, was reported to be associated
with bad prognosis (Rosenwald et al, 2003), we evaluated MCM
protein expression by immunohistochemistry in MCL. Out of the
family of MCM proteins we chose MCM6 for our analysis, because
a highly reliable monoclonal antibody against this MCM family
member was available (Heidebrecht et al, 2001).
First we ranked the patients according to their MCM6
expression level and divided into four equal groups (quartiles).
Kaplan–Meier analysis showed significant differences in the
overall survival time in different quartiles (Figure 4, Table 3,
Po0.0001). Second, for the Kaplan–Meier analysis, we chose
different MCM6 expression levels according to the categories of
Ramnath et al (2001). In the group under 25% MCM6-positive
cells, the median overall survival time was despite the long follow-
up time not reached, indicating that this group of patients has an
excellent prognosis. The other patients with higher MCM6
expression had a significantly shorter overall survival, with a
median of 38.2 months in the group 425–50% positive cells
compared to the group representing 450–75% MCM6-positive
cells, which had a median of 30.0 months. The highly proliferating
group of 75% and more MCM6-positive cells had a median
survival time of only 16 months (Po0.0001). In the multivariate
Cox regression analysis which included Ki-67, only MCM6
expression (Po0.0001) and IPI score (P¼0.0018) proved to be
prognostic factors for clinical outcome of patients with MCL.
These results clearly indicate that MCM6 expression is a much
stronger predictor of overall survival in MCL than Ki-67. Further,
the data confirm the data from gene expression profiling
studies that MCM protein expression can predict overall survival
in MCL. It will be interesting to evaluate if MCM2 expression
by immunohistochemistry is as effective as MCM6 expression
reported here.
Minichromosome maintenance protein 6 expression in MCL
ranged from 12.0 to 95.6%, with a mean of 60.9%. In contrast,
the Ki-67 index was significantly lower, with a mean of 19.8%
and a range between 2.2 and 64.2%. Nevertheless, the Ki-67 and
MCM6 indices showed a good correlation (Figure 3, Po0.0001).
These data are in line with others (Ramnath et al, 2001; Helfenstein
et al, 2004), indicating that the ratio of MCM6- and Ki-67-positive
cells is larger in MCL than the Ki-67 expressing cells. Blastoid
variants usually have a more aggressive clinical behaviour than
classical types, and the proliferation indices in the blastoid
subtypes are usually higher (Schrader et al, 2004). To our surprise,
there were no significant differences in MCM6 expression
(P¼0.27) between the different cytological subtypes. Although
both markers MCM6 and Ki-67 are expressed in the G1, S, G2 and
M phases of the cell cycle, the higher number of MCM6-positive
cells can be explained by the expression of MCM6 in the early G1
phase, when Ki-67 expression cannot be detected (Heidebrecht
et al, 2001). Compared to stimulated peripheral blood mono-
nuclear cells (ratio: mean: 1.470.5; Heidebrecht et al, 2001), the
difference between Ki-67 and MCM6 positive cells in our series of
MCLs is higher (mean: 4.774.6). These data show that a subset of
mantle cell tumour cells is arrested in the early G1 phase and the
MCM6-positive cells do not necessarily represent the real
proliferating compartment of the lymphoma. This fact could also
explain why the blastoid and classical subtype had no significant
difference in the MCM6 expression as a marker for the G1 arrest
and not as a proliferation marker. As this cell cycle arrest has been
shown by others (Stoeber et al, 2001; Eward et al, 2004; Obermann
et al, 2005; Tachibana et al, 2005), we could demonstrate that this
has a clinical relevance in patients with MCLs. Our data on
expression of repp86 in MCL (Schrader et al, 2005) showed that
real proliferation activity is an important prognostic factor in
MCL. On the other hand, patients with cell arrest (G1 arrest)
indicated by high MCM6 expression also predict survival in this
disease.
The typical translocation t(11;14)(q13;q32) of MCLs causes an
overexpression of the cell cycle regulating protein cyclin D1, that
binds to the cyclin-depending kinases (CDK) 4 and 6 and therefore
plays an important role in the control of the G1 phase in the cell
cycle (Hunter and Pines, 1994). The cyclin/CDK complexes are
important for progression of cells into S phase. Taking this
molecular mechanism in consideration, it is more surprising that a
majority of MCL tumour cells are not in S–M–G2 phases, but in
G1 arrest. Future research has to combine markers of cell
proliferation and cell cycle arrest with markers of other biological
processes like apoptosis (Martinez et al, 2003) to get insight into
the biology and explain the heterogeneous therapeutic response of
this disease.
In conclusion, high MCM6 expression indicates early G1-phase
arrest, and is a new prognostic marker in MCL superior to other
clinical prognostic parameters and Ki-67 expression.
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